Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Nov 7, 2021; 27(41): 7159-7172
Published online Nov 7, 2021. doi: 10.3748/wjg.v27.i41.7159
Table 1 Patient demographic and clinical characteristics
All patients
Propensity-score matched patients
Open (n = 211)
Laparoscopy (n = 137)
P
Open (n = 102)
Laparoscopy (n = 102)
SMD
Age (yr)29.2 ± 9.729.2 ± 9.00.97628.8 ± 9.028.6 ± 8.7-0.026
Gender, male153 (72.5)95 (69.3)0.54678 (76.5)72 (70.6)-0.134
BMI (kg/m2)18.8 ± 3.218.9 ± 2.80.82219.0 ± 3.318.9 ± 2.8-0.041
Any smoking history41 (19.4)33 (24.1)0.34821 (20.6)20 (19.6)-0.025
Previous abdominal surgery23 (10.9)10 (7.3)0.34910 (9.8)8 (7.8)-0.069
Montreal classification
Behavior< 0.001-0.044
Inflammatory (B1)2 (0.1)2 (1.5)2 (2.0)2 (2.0)
Stricturing (B2)38 (17.5)52 (38.0)30 (29.4)26 (25.5)
Penetrating (B3)172 (82.0)83 (60.6)70 (68.6)74 (72.5)
Location 0.218-0.060
Terminal ileal (L1)68 (32.2)50 (36.5)36 (35.3)37 (36.3)
Colonic (L2)10 (4.7)2 (1.5)6 (5.9)2 (2.0)
Ileocolic (L3)133 (63.0)85 (62.0)60 (58.8)63 (61.8)
Disease duration (mo)49.8 ± 50.968.1 ± 59.30.00361.5 ± 57.467.0 ± 57.80.095
Perianal CD103 (48.8)57 (41.6)0.22645 (44.1)45 (44.1)0.000
Family history of CD5 (2.4)5 (3.6)0.5234 (3.9)4 (3.9)0.000
Extra-intestinal CD manifestation31 (14.7)18 (13.1)0.75413 (12.7)10 (9.8)-0.093
Comorbidity21 (10.0)5 (3.6)0.0362 (2.0)4 (3.9)0.116
Hypertension4 (1.9)0 (0.0)0.1571 (1.0)0 (0.0)
Diabetes mellitus2 (0.9)1 (0.7)1.0000 (0.0)1 (1.0)
Others15 (7.1)5 (3.6)0.2391 (1.0)4 (3.9)
ASA score, 3-47 (3.3)2 (1.5)0.3973 (2.9)2 (2.0)2
Emergency17 (8.1)9 (6.6)0.6806 (5.9)7 (6.9)0.040
Preoperative data
Hemoglobin (g/dL)11.5 ± 1.511.5 ± 1.90.78011.4 ± 1.411.4 ± 1.80.037
Albumin (g/dL)3.1 ± 0.53.2 ± 0.50.1403.1 ± 0.53.2 ± 0.50.075
Transfusion40 (19.0)26 (19.0)1.00022 (21.6)20 (19.6)2
Preoperative medications
Steroids44 (20.9)25 (18.2)0.58422 (21.6)15 (14.7)-0.179
Immuno-modulators96 (45.5)67 (48.9)0.58348 (47.1)50 (49.0)0.039
Biologics29 (13.7)26 (19.0)0.22917 (16.7)16 (15.7)-0.027
Indication for surgery< 0.001
1Fistula versus others83 (39.3)34 (24.8)0.02233 (32.4)32 (31.4)0.021
2Obstruction versus others39 (18.5)54 (39.4)< 0.00131 (30.4)26 (25.5)-0.042